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Amyotrophic lateral sclerosis (ALS) is a devastating disease for which there are no effective drug treatments to date. Recent advances in Gene Therapy
open up the possibility of developing an effective treatment aiming at halting or delaying the degeneration ofmotor neurons.Viral vectors such as lentiviral
vectors and adeno-associated virus can transfer genes into many different types of primary neurons from a broad range of species including man and the
resulting gene expression is long-term. Numerous animal studies have now been undertaken with these vectors and correction of disease models has been
obtained. These vectors have been refined to a very high level and can be produced safely for the clinic. However, we believe that there are some major
issues that need to be addressed in order to see aGene Therapy approachwith viral vectors proceed to the clinic for ALS patients. This reviewwill describe
the general features of lentiviral vectors. It will then describe some key examples of gene transfer and genetic correction in animal models of motor neuron
disease. The prospects for the clinical evaluation of lentiviral vectors for the treatment of human motor neuron disease will be outlined.
© 2006 Elsevier B.V. All rights reserved.Keywords: Gene Therapy; ALS; Motor neuron; Viral vector; Animal model1. Introduction
Gene Therapy approaches involving the use of viral vectors
offer a promising strategy for delivery of genes to enhance motor
neuron survival. Vectors based on lentiviruses and adeno-asso-
ciated virus (AAV) are proving to be particularly effective for the
treatment of neurological disorders [1,2]. These vectors are attrac-
tive for their simplicity and their high transduction efficiency for
neurons [3]. Here we focus on lentiviral vectors which have several
advantages for the treatment of neurological disorders. These vec-
tors have been refined to a very high safety and efficiency levels [4–
6]. The following properties make them suitable for Gene Therapy
approaches: (i) Lentiviriral vectors efficiently transduce not only
dividing but also non-dividing cells, such as neurons [7–10]. (ii)
They have a large cloning capacity (8–10 kb). (iii) They integrate
genes into the chromosome of the target cells, leading to stable
long-term expression [4,9,11–14]. Long-term and stable expression
at therapeutic levels is often essential for gene delivery to treat
neurological disorders. Lentiviral vectors maintain expression for⁎ Tel.: +44 114 271 3204.
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doi:10.1016/j.bbadis.2006.05.003up to 16 months [15,16]. (iv) Based on rodent and monkey studies,
lentiviral vectors do not give rise to immunological complications
that can compromise the viability of the transduced cells [10,11,15].
However, there is no sufficient evidence about the lack of these
complications in man. Human studies are therefore needed to
address this issue, in particular, whose investigating the effects after
repeated administration of these vectors. Finally, lentiviral vector
transduction does not appear to affect electrophysiological pro-
perties of neurons [17].
2. Lentiviral vectors-mediated gene transfer to the nervous
system
Transduction of neuronal cells using lentiviral vectors both in
rodent and primate has beenwidely demonstrated [1,18]. Lentiviral
vectors can be split into two groups, the primate such as those based
on human immunodeficiency virus (HIV) [14], simian immuno-
deficiency virus (SIV) [19] and non-primate such as those derived
from equine infectious anaemia virus (EIAV) [20] and Feline
immunodeficiency virus (FIV) [21]. There has been a continuing
evolution of the design of lentiviral vectors with the trend being to
remove as much viral sequence as possible from the transfer
genome. Surprisingly, it was possible to construct efficient vectors
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very simple vector systems. This is important because the accessory
and regulatory genes are biologically active and can cause detri-
mental effects on cells including oncogenesis (tat), apoptosis (vpr),
MHC down regulation (nef) and differentiation (vpu) (for a review
see [22]). Vectors lacking these genes are called minimal vector
systems and they have been well developed from HIV-1 [23,24],
EIAV [20], FIV [21,25] and similar strategies are being applied to
other lentiviruses e.g. SIV [26] and all such vector systems share
similar features.
Lentiviruses can be efficiently pseudotyped with different enve-
lopes such as VSV-G [9,27–29], rabies-G [9,30], Mokola and
Ebola [28,29] filovirus envelope protein [31] and the challenge
virus standard (CVS) [32]. Currently, the HIV and EIAV-based
vectors are themost attractive gene delivery systemswith respect to
neuronal tropism, long term expression [2,33], sustained transduc-
tion of skeletal muscles [34] and retrograde transport from muscle
to spinal motor neurons [9]. The VSV-G pseudotyped lentiviral
vectors expressing the reporter gene or therapeutic genes have a
broad capacity to transduce a wide variety of cell types in vitro, but
exhibit a preference for neuronal phenotypes in vivo. It was further
demonstrated that the rabies-G pseudotyped EIAV vectors allowed
entry into the central nervous system and transduction of spinal
motor neurons after an intramuscular injection in rodent [9]. Thus
this technology allows non-invasive peripheral administration of
therapeutic genes and consequent transduction of spinal cordmotor
neurons from muscle delivery. These observations present novel
opportunities in designing therapeutic strategies for different motor
neuron disease.
Recent studies have demonstrated the remarkable efficacy of
Lentiviral-mediated Gene Therapy approaches to neurological
disorders [2,35]. Numerous animal studies have now been under-
taken with these vectors and correction of disease models has been
obtained. For example, in vivo lentiviral delivery of the antia-
poptotic gene Bcl-xL or nerve growth factor gene has been shown
to prevent degeneration of cholinergic basal forebrain neurons [36].
Furthermore, lentiviral delivery of glial-cell line derived neuro-
trophic factor (GDNF) efficiently prevented the loss of dopami-
nergic nigrostriatal neurons in rodent and monkey models of
Parkinson's disease [11,15,27]. Lentiviral vectors also provide a
new strategy for in vivo modeling of human diseases; for example
the lentiviral-mediated overexpression of mutated human α-synuc-
lein or huntingtin genes in basal ganglia induces neuronal patho-
logy in animals resembling PD and HD in man [37,38]. Recent
reports have demonstrated the utility of these vectors for arrayed
screens and its application to biological discovery [39]. These
studies provide great optimism for the future utility of lentiviral
vectors in research and therapy of neurodegenerative diseases.
3. Gene Therapy for ALS
Motor neuron diseases (MNDs) are a group of rapidly fatal
conditions characterized by paralysis and a variety of other motor
deficits. The most well-known MND is ALS also known as Lou
Gehrig's disease. It was first defined by Charcot in 1874 [40]. It
typically afflicts individuals inmiddle adult life, leading to paralysis
and death within 3 to 5 years [41]. ALS is a progressive neuro-degenerative disease that mainly results from selective degenera-
tion ofmotor neurons in the cortex, brain stem, and spinal cord [42].
About 10% of the ALS cases are familial, and 20% of those are
associated with dominantly inherited mutations in SOD1, the gene
that encodes human CuZn-superoxide dismutase (SOD1) [43].
Transgenic mice over-expressing a mutated form of human SOD1
develop a severe and progressive MND closely resembling the
human disease [44,45] and represent therefore the best animal
models for ALS. Deleterious effects of the mutant SOD1 protein
arise through a novel and yet unknown process. Multiple lines of
evidence from cell cultures and transgenic animal models indicate
that the mutant SOD1 gene acquires toxic gain of function, but the
protein still retains normal enzymatic activity and stability [45].
Several mechanisms by which expression of mutant SOD1 may
lead to chronic motor neuron degeneration have been suggested.
The 4 key pathogenetic hypotheses comprise genetic factors, oxi-
dative stress, glutamatergic toxicity and protein misfolding/aggre-
gation (for review [46,47]).
Despite worldwide efforts ALS patients have no significant
treatment options, in part because ALS has complex etiology that
remains insufficiently understood and methods to deliver thera-
peutically active neuroprotective growth factors are still ineffi-
cient. Riluzole, an inhibitor of synaptic glutamate release, is so far
the only approved drug for treatment of human ALS [48,49]. In
mice overexpressing the mutated G93A form of the superoxide
dismutase-1 (SODG93A) gene—a widely used animal model of
ALS [44], riluzole modestly (by an average of 10%) prolonged
survival without affecting disease onset [50]. Several pharmaco-
logical agents, including caspase inhibitor zVAD-fmk, creatine,
minocycline, celecoxib and arimoclomol, were tested in animal
models of ALS and promising effects were observed [51–55]. A
number of these drugs are currently being investigated in clinical
trials as potential therapy for ALS [56–59].
4. Lentiviral-mediated neuroprotection for motor neurons
The isolation and cloning of a number of neurotrophic factors
has created new possibilities for the treatment of neurodege-
nerative diseases. Neurotrophic factors are naturally occurring
proteins which are essential for neuronal survival and differen-
tiation during development, but also for the maintenance of
normal function in the adult nervous system. Several neurotrophic
factors including vascular endothelial growth factor (VEGF),
insulin-like growth factor-I (IGF-I) and glial cell line-derived
neurotrophic factor (GDNF) were evaluated in experimental
models of ALS [30,60,61]. VEGF and IGF-I were found to be
most efficacious [30,61,62]. However when administered either
systemically or into the cerebrospinal fluid of ALS patients,
trophic factors such asGDNF and IGF-1 proteins failed to prevent
motor neuron death and resulted in undesirable side effects [63–
65] limiting dosage options. However, the localised delivery of
therapeutic molecules using Gene Therapy may circumvent some
of the toxic side effects that result from the bolus administration of
recombinant proteins and may increase their bioavailability.
GeneTherapy approaches expand the therapeutic options for the
treatment of motor neuron disease. This is because potentially any
gene product can be delivered without the need to manufacture
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encoding neurotrophic factors, growth factors or anti-apoptotic
genes. Gene Therapy can be used to restore beneficial protein levels
by gene replacement or to deliver proteins or nucleic acids that can
inhibit deleterious gene expression.
Several studies have shown the remarkable ability of lentiviral
vectors to transduce motor neurons both in vitro and in vivo
[30,66,67]. Recently, lentiviral vectors have been extensively
used as a means to perform therapeutic strategies in animal mo-
dels of motor neuron diseases such as ALS and SMA [30,68–70].
For example, when using the lentiviral gene transfer system to
deliver vascular endothelial growth factor (VEGF) to motor
neurons in the well established SOD1G93A mouse ALS model,
VEGF treatment prevented cell death and prolonged survival of
SOD1G93Amice [30].Most importantly, lentiviral-mediatedGene
Therapy achieved one of the highest therapeutic effects reported
in the field to date. We have also reported that lentiviral vectors
encoding for human survival motor neuron (SMN) was
successfully used to restore SMN protein levels in SMA type 1
fibroblasts [68]. The same vector system was used to treat SMA
type 1 mouse model. The treatment restored SMN to motor
neurons, reduced motor neuron death and increased the life
expectancy compared to control groups [68]. On the other hand,
Hottinger and colleagues showed that using the facial nerve lesion
model in adult Balb/C mice, expression of GDNF close to motor
neuron cell bodies of the facial nucleus using a lentiviral vector
system leads to a complete protection against lesion-induced
death [67]. Taken together these data reveal that Gene Therapy
approaches have been successful in animal models of motor
neuron diseases including ALS.
5. Interfering RNA as a therapy for familial ALS
RNA interference (RNAi) is a biological process based on
naturally occurring phenomenon in organisms such as plants,
Caenorhabditis elegans,Drosophila and mammals. RNAimediate
highly specific gene silencing and provides an exciting prospect as
a novel therapeutic strategy for a wide range of disorders. Several
research groups can now create small inhibitory RNAmolecules to
silence the expression of genes involved in genetic disorders.
Although small interfering RNA (siRNA) has now been validated
as a powerful research tool, advancing such an approach to
therapeutic application presents a number of problems. Selection of
an efficient siRNA target site is not as simple as choosing any 21
nucleotide sequence along the length of a gene. Different siRNA
sequences have different efficiencies at mediating target gene
silencing and indeed may have no effect whatsoever. Fortunately,
key parameters that are necessary to design an efficient siRNA
molecule are becoming clear and these include G/C content, RNA
stability at the 5′-antisense end, lack of inverted terminal repeats
and the position of particular bases at critical sites along the siRNA
sequence [71,72].
Probably the most significant problem to the advancement of
siRNA from a research tool to a therapeutic agent is the iden-
tification of efficient delivery methods to enable efficient and
controlled gene silencing within the relevant target cell popu-
lations. Systemic administration of relatively large volumes ofsiRNA using high-pressure tail vein injection was previously
demonstrated to mediate silencing of target gene expression in
the liver and to a lesser extent in the lung, kidney, spleen and
pancreas [73,74]. However, gene silencing was transient and
uncontrolled. More recently chemical modification of siRNA
was demonstrated to increase stability of siRNA following
systemic delivery and mediate a significantly higher efficacy of
target gene silencing compared with delivery of ‘naked’ siRNA
molecules [75]. The development of viral vectors to express
short hairpin RNA (shRNA) molecules which are processed into
functional siRNAs molecules in the host cell provides a
promising approach for therapeutic delivery of siRNAs [76].
Such vectors provide the potential for long-term expression of
functional siRNA molecules and incorporation of regulatable
elements has allowed regulated expression of siRNAs and
subsequent gene silencing to be achieved [77,78].
Several dominantly inherited diseases provide particularly
good candidate disorders for investigating siRNA-based thera-
pies. Critically, some of these diseases have particularly relevant
animal models, which provide a good platform for determining
potential therapeutic efficacy. Some impressive efficacy data are
emerging, in particular the use of viral vectors for RNAi delivery
to treat the dominantly inherited neurological disorders, including
Huntington's disease and related polyglutamine disorders, dysto-
nia, and familial Alzheimer's disease [79–82]. Approximately
20% of familial cases of ALS are caused by dominantly inherited
mutations in the gene encoding cytosolic superoxide dismutase
(SOD1) conferring a toxic gain of function to this protein [43,44].
Silencing of mutant SOD1 expression provides a possible
therapeutic strategy for treating such cases of FALS. Recent
studies have investigated the therapeutic potential of using siRNA
in mouse models of ALS [69,70,83]. Only one study showed
limited benefits for treating ALS symptoms in ALS model [83].
Treatment of SOD1G93A mice with EIAV-based lentiviral vector
system resulted in an efficient and specific reduction of hSOD1
expression and improved survival in vulnerable motor neuron
populations of the brain stem and spinal cord. Furthermore,
hSOD1 silencing mediated an improved motor performance in
these animals resulting in a significant delay in the onset of ALS
symptoms by over 100% and an extension in survival by nearly
80% of their normal life span [69]. The retrograde transport
capacity of EIAV-based lentiviral vectors pseudotyped with
particular envelope glycoproteins was used to specifically deliver
shRNAs targeted against human mutant SOD1 to vulnerable
motor neuron populations by simple intramuscular injection. A
similar approach was adopted to express functional RNAi
molecules specifically targeted against the human SOD1
(hSOD1) gene using AAV vectors and some limited success
has been reported [83]. Alternatively, direct injections of lentiviral
vectors expressing inhibitory siRNA into the spinal cord in animal
model of ALS has demonstrated the capacity of RNAi to silence
mutant SOD1 [70]. These studies highlight the therapeutic
potential of siRNA in vivo for a dominantly inherited disease.
Since SOD-1 linked FALS is caused by a stable mutation in the
SOD-1 gene an effective siRNA-based therapy would require
sustained delivery of the active molecule throughout the lifetime
of the patient. Lentiviral vectors such as those used in the studies
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integrated into the host cell genome following transduction.
Therefore, transgene expression from these vectors is long-term
and may provide an ideal delivery vector for siRNA-mediated
therapy of dominantly inherited diseases such as FALS.
For some dominantly inherited diseases, the translation to
therapy of RNAi may require an allele-specific strategy. RNAi
would therefore ideally silence the mutant allele but not its
normal counterpart. Allele-specific approach has already been
reported for various neurological disorders genes in vitro,
including APP in familial Alzheimer's disease, MJD1 in
Machado–Joseph disease, and SOD1 in ALS. Studies are now
required to determine whether the allele-specific silencing could
be extended to animal models of ALS. The targeted region can
be the mutation itself in SOD1 gene. However, the design of
RNAi for clinical applications in SOD1-linked ALS cases can
be limited by the presence of over a hundred of different
mutations in SOD1 gene. In this case, combination of RNAi
with a viral vector expressing wild type SOD1 may provide
alternative strategy for allele-specific approach for ALS.
However, siRNA treatment of FALS is relevant to only a
minority of ALS patients.
6. Clinical prospects for lentiviral vectors
Gene Therapy approaches involving the use of viral vectors
offer a promising strategy for the delivery of genes to enhance
motor neuron survival and repair. Lentiviral vectors are powerful
tools to gene transfer into the nervous system. Various research
groups are investigating multiple gene transfer strategies using
lentiviral vectors to improve motor neuron survival in animal
models of ALS. In addition, Lentiviral vector-mediated gene
transfer has been validated in several animal models of
neurological disorders including Parkinson's disease and Alzhei-
mer's disease (for review, [2]). The safety testing and manufac-
turing protocols for these vectors are also being vigorously
developed (reviewed in [84,85]). A number of clinical protocols
are now being prepared and we anticipate seeing these move
through the regulatory process. There seems to be a good rationale
for testing lentiviral vectors quite soon in late stage neurological
disease where there are no other reasonable treatment options.We
believe that there are twomajor issues that need to be addressed in
order to see a Gene Therapy approach with lentiviral vectors
proceed to the clinic for ALS patients. First, making a stable
producer line that will produce clinical grade vector is critical for
ALS clinical trial, where a lot of virus will be required per patient
(several injections in several muscle groups). Second, careful
assessment of delivery, biodistribution and toxicity issues of the
lentiviral vector systems in primates is needed.References
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